´ëÇÑÇǺΰúÇÐȸ ¼¿ïÁöºÎȸ Ä¡·á½ÉÆ÷Áö¿ò : 2021-06-26
±³À°ÀÏÀÚ : 2021-06-26
±³À°Àå¼Ò : »ïÁ¤È£ÅÚ, ¶óº¥´õ·ë
±³À°ÁÖÁ¦ : ´ëÇÑÇǺΰúÇÐȸ ¼¿ïÁöºÎȸ Ä¡·á½ÉÆ÷Áö¿ò
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼¿ïÁöºÎȸ
´ã´çÀÚ : Á¤ÇýÁ¤ ±³¼ö
¿¬¶ôó : 02-2260-7315
À̸ÞÀÏ : humeong01@nmc.or.kr
±³À°Á¾·ù : ÇǺΰú
Âü¼®¿¹»óÀοø : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 500,000¿ø
ºñ°í ȸ¿ø: ¾øÀ½ / ´ëÇÑÇǺΰúÇÐȸ ¼¿ïÁöºÎȸ ºñȸ¿ø: 50¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-26 ¶óº¥´õ 14:10~14:30 Practical use of immunosuppressive drugs in dermatology ±èµµ¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-26 ¶óº¥´õ 14:30~14:50 IL-17 vs IL23; considerations in clinical practice ÃÖ¿ë¹ü(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 06-26 ¶óº¥´õ 14:50~15:10 Cutaneous manifestations associated with COVID-19 and the use of immunosuppressant and biologics in COVID 19 vaccination ¹æöȯ(°¡Å縯ÀÇ´ë)
Åä·Ð 06-26 ¶óº¥´õ 15:10~15:20 Q&A ±èµµ¿µ, ÃÖ¿ë¹ü, ¹æöȯ()
±³À°½Ã°£ 06-26 ¶óº¥´õ 15:20~15:40 Novel therapeutics by advances in the pathophysiology of atopic dermatitis ±èÇý¿ø(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06-26 ¶óº¥´õ 15:40~16:00 Recent advances in understanding and managing rosacea ¹Ú±Í¿µ(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 06-26 ¶óº¥´õ 16:00~16:20 Treatment options for severe and refractory alopecia areata ÀÌ¿µ(Ãæ³²ÀÇ´ë)
Åä·Ð 06-26 ¶óº¥´õ 16:20~16:30 Q&A ±èÇý¿ø,¹Ú±Í¿µ, ÀÌ¿µ()
ÈÞ½Ä 06-26 16:30~16:50 ()
±³À°½Ã°£ 06-26 ¶óº¥´õ 16:50~17:10 Truth and faulsity of LED in its application for dermatologic disorders ÇãâÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-26 ¶óº¥´õ 17:10~17:30 Present and future of senolytics in skin senescence À̽ÃÇü(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-26 ¶óº¥´õ 17:30~17:50 Controversy on therapeutic strategy for postinflammatory hyperpigmentation in laser treatment ÀÌÇØ¿õ(·çÀÌÇǺΰú)
Åä·Ð 06-26 ¶óº¥´õ 17:50~18:00 Q&A ÇãâÈÆ, À̽ÃÇü, ÀÌÇØ¿õ()